Targeted Exosomes for Drug Delivery: Biomanufacturing, Surface Tagging, and Validation

Yingnan Si,Seulhee Kim,Eric Zhang,Yawen Tang,Renata Jaskula‐Sztul,James M. Markert,Herbert Chen,Lufang Zhou,Xiaoguang Liu,Xiaoguang (Margaret) Liu
DOI: https://doi.org/10.1002/biot.201900163
2019-10-20
Biotechnology Journal
Abstract:<p>Exosomes hold great potential to deliver therapeutic reagents for cancer treatment due to its inherent low antigenicity. However, several technical barriers need be overcome before widely clinical applications, such as low productivity and ineffective cancer targeting. The present study aimed at creating a new biomanufacturing platform of cancer‐targeted exosomes for drugs delivery. Specifically, we created a scalable, robust, high‐yield, cell line‐based exosomes production process in stirred‐tank bioreactor, and developed an efficient surface tagging technique to generate mAb‐exosomes. The in vitro characterization using transmission electron microscopy, NanoSight nanoparticle tracking analysis and Western blotting confirmed the high quality of exosomes. Flow cytometry and confocal laser scanning microscopy imaging demonstrated mAb‐exosomes had strong surface binding to cancer cells. Furthermore, to validate the targeted drug delivery efficiency, we loaded Romidepsin, a histone deacetylase inhibitor, into mAb‐exosomes. The in vitro anti‐cancer toxicity study showed high cytotoxicity of mAb‐exosome‐Romidepsin to cancer cells. Finally, the in vivo study using tumor xenograft animal model validated the cancer targeting specificity, anti‐cancer efficacy, and drug delivery capability of the targeted exosomes. In summary, we developed new techniques enabling targeted exosomes for drug delivery to support large‐scale animal studies and facilitate the translation from research to clinics.</p><p>This article is protected by copyright. All rights reserved</p>
biotechnology & applied microbiology,biochemical research methods
What problem does this paper attempt to address?